A multiomic analysis led by the IrsiCaixa AIDS Research Institute has uncovered genetic and immune mechanisms in some ...
Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...
GlobalData on MSN2d
Gilead and MSD to advance once-weekly HIV treatment to Phase IIIThe companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Improving HIV Treatment in Children and Adolescents -- The Right Way July 18, 2024 — Globally, around 2.6 million children and adolescents are currently living with HIV, the majority of them in ...
Namibia has made significant strides in stemming the spread of HIV and AIDS through education and prevention. However, for ...
Two posters compared health care resource utilization (HCRU) and financial burdens of people living with HIV with a non-HIV ...
Like its English-language predecessor, which launched in 2016, this Spanish-language patient community from MyHealthTeam is ...
With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...
Psoriasis is an autoimmune disease that causes your body to overproduce skin cells. It most commonly causes thick, raised skin plaques to develop on your body. When psoriasis affects your nails ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback